Dr. Brock Schuman — Biotechnology, therapeutics and drug design
Brock’s research has focused on enablement of therapeutic discovery and development from structural biology to transgenic and behavioral animal models. In 2012 he received his PhD in biochemistry, and subsequently pursued both private and public and sector drug development post docs in Toronto. He founded Azor Biotek in 2019 to advance the state of the art in RNA drug targeting, and is a co-founder of the non-profit organization the Canadian Association for Responsible Artificial Intelligence in Medicine. Azor leverages AI for the development of novel small molecule therapeutics, and develops biomimetic reactors for synthesis of natural drug products and their derivatives.
Dr. Javier Alfaro — Bioinformatics and biomedical artificial Intelligence
Dr. Javier Alfaro is a researcher specializing in immunology and biodiagnostics, with a focus on cancer biomarker discovery and the design of immune-related treatments and vaccines. Utilizing a multi-omic approach, he explores immune-system interactions with disease to identify new therapeutic targets. Dr. Alfaro leverages advanced computational tools and artificial intelligence to develop RNA-based therapies and vaccines and enhancing precision medicine solutions. His research integrates high-throughput sequencing and mass spectrometry data to drive translational research, aiming to transform scientific discoveries into practical medical applications through collaboration.